TGTX (TG Therapeutics) Notes Receivable: $0.0 Mil (As of Mar. 2026)


TGTX TG Therapeutics Inc TGTX
82 GF Score
Price $53.31
GF Value $58.75
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is TG Therapeutics Notes Receivable?

TG Therapeutics TGTX -0.39% 82 Notes Receivable is $0.0 Mil as of Mar. 2026. GuruFocus rates TGTX with a GF Score™ of 82/100 and a GF Value™ of $58.75 (Fairly Valued). The stock has 8 warning signs investors should review.

TG Therapeutics's Notes Receivable for the quarter that ended in Mar. 2026 was $0.0 Mil.

TG Therapeutics Notes Receivable Related Terms

TG Therapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for TG Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TG Therapeutics Notes Receivable Chart

TG Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TG Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TGTX
82GF Score
TG Therapeutics Inc TGTX
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TG Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.0 Mil mean?
TG Therapeutics (TGTX) has a Notes Receivable of $0.0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on TG Therapeutics and its competitors.
Is TG Therapeutics' Notes Receivable too high?
TG Therapeutics' current Notes Receivable is $0.0 Mil. Overall, TG Therapeutics has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' Notes Receivable compare to HALO and KYMR?
TG Therapeutics' Notes Receivable of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on TG Therapeutics and its competitors. TG Therapeutics's current Notes Receivable is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (TGTX) is currently considered Fairly Valued. The stock's GF Value™ is $58.75, compared to a current price of $53.31 — trading 9.3% below its estimated fair value. The current Notes Receivable is $0.0 Mil. TG Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For TG Therapeutics (TGTX), the current Notes Receivable is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TG Therapeutics (TGTX) Overvalued in 2026?

Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued. The current stock price of $53.31 is trading 9.3% below its estimated GF Value™ of $58.75. GuruFocus considers TG Therapeutics to be Fairly Valued.

Key valuation signals for TGTX:

  • Notes Receivable: $0.0 Mil
  • GF Value™: $58.75 vs. price of $53.31 (9.3% below fair value)
  • GF Score™: 82/100 with 8 warning signs

No single metric tells the full story. See the TGTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TG Therapeutics Business Description

Other Exchanges 1TGTX:ItalyNKB2:Germany
Address 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
82GF Score

Get the complete analysis for TGTX

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$53.31
Price
$58.75
GF Value